Skip to main content
main-content

01.12.2018 | Research | Ausgabe 1/2018 Open Access

Health Research Policy and Systems 1/2018

Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes

Zeitschrift:
Health Research Policy and Systems > Ausgabe 1/2018
Autoren:
Matthew Glover, Erin Montague, Alexandra Pollitt, Susan Guthrie, Stephen Hanney, Martin Buxton, Jonathan Grant
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:https://​doi.​org/​10.​1186/​s12961-017-0276-7) contains supplementary material, which is available to authorized users.

Abstract

Background

Building on an approach applied to cardiovascular and cancer research, we estimated the economic returns from United Kingdom public- and charitable-funded musculoskeletal disease (MSD) research that arise from the net value of the improved health outcomes in the United Kingdom.

Methods

To calculate the economic returns from MSD-related research in the United Kingdom, we estimated (1) the public and charitable expenditure on MSD-related research in the United Kingdom between 1970 and 2013; (2) the net monetary benefit (NMB), derived from the health benefit in quality adjusted life years (QALYs) valued in monetary terms (using a base-case value of a QALY of £25,000) minus the cost of delivering that benefit, for a prioritised list of interventions from 1994 to 2013; (3) the proportion of NMB attributable to United Kingdom research; and (4) the elapsed time between research funding and health gain. The data collected from these four key elements were used to estimate the internal rate of return (IRR) from MSD-related research investments on health benefits. We analysed the uncertainties in the IRR estimate using a one-way sensitivity analysis.

Results

Expressed in 2013 prices, total expenditure on MSD-related research from 1970 to 2013 was £3.5 billion, and for the period used to estimate the rate of return, 1978-1997, was £1.4 billion. Over the period 1994–2013 the key interventions analysed produced 871,000 QALYs with a NMB of £16 billion, allowing for the net NHS costs resulting from them and valuing a QALY at £25,000. The proportion of benefit attributable to United Kingdom research was 30% and the elapsed time between funding and impact of MSD treatments was 16 years. Our best estimate of the IRR from MSD-related research was 7%, which is similar to the 9% for CVD and 10% for cancer research.

Conclusions

Our estimate of the IRR from the net health gain to public and charitable funding of MSD-related research in the United Kingdom is substantial, and justifies the research investments made between 1978 and 1997. We also demonstrated the applicability of the approach previously used in assessing the returns from cardiovascular and cancer research. Inevitably, with a study of this kind, there are a number of important assumptions and caveats that we highlight, and these can inform future research.
Zusatzmaterial
Additional file 1: Appendix 1. Funding data. (XLSX 21 kb)
12961_2017_276_MOESM1_ESM.xlsx
Additional file 2: Appendix 2. Health gain (i.e. net monetary benefit) data. (XLSX 61 kb)
12961_2017_276_MOESM2_ESM.xlsx
Additional file 3: Appendix 3. Guideline data. (XLSX 16 kb)
12961_2017_276_MOESM3_ESM.xlsx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Health Research Policy and Systems 1/2018 Zur Ausgabe